Supernus Pharmaceuticals, Inc. - Understand $supn stock

$SUPN Market Cap: $2.051 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$652.0M

TTM

Gross Margin

89.02%

TTM

Net Earnings

$59.71M

TTM

Current Assets

$640.0M

Q3 2024

Current Liabilities

$291.5M

Q3 2024

Current Ratio

219.55%

Q3 2024

Total Assets

$1.343B

Q3 2024

Total Liabilities

$335.6M

Q3 2024

Book Value

$1.007B

Q3 2024

Cash

$31.67M

Q3 2024

P/E

34.35

Nov 29, 2024 EST

Free Cash Flow

$172.0M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$607.5M	$667.2M	$579.8M	$520.4M	$392.8M	$408.9M	$302.2M	$215.0M	$147.5M	$92.70M	$12.02M	$1.480M	$803.0K	$106.0K	$37.90M	$8.900M	$4.200M
YoY Change	-8.95%	15.09%	11.41%	32.5%	-3.95%	35.29%	40.58%	45.76%	59.12%	671.28%	712.09%	84.31%	657.55%	-99.72%	325.84%	111.9%	-33.33%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	$607.5M	$667.2M	$579.8M	$520.4M	$392.8M	$408.9M	$302.2M	$215.0M	$147.5M	$92.70M	$12.02M	$1.480M	$803.0K	$106.0K	$37.90M	$8.900M	$4.200M
Cost Of Revenue	$83.78M	$87.22M	$75.06M	$52.46M	$16.66M	$15.36M	$15.22M	$12.00M	$8.400M	$5.800M	$1.104M	$0.00	$0.00
Gross Profit	$523.7M	$580.0M	$504.7M	$467.9M	$376.1M	$393.5M	$287.0M	$203.0M	$139.0M	$86.90M	$10.92M	$1.500M	$800.0K
Gross Profit Margin	86.21%	86.93%	87.05%	89.92%	95.76%	96.24%	94.97%	94.42%	94.24%	93.74%	90.81%	101.35%	99.63%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Selling, General & Admin	$336.4M	$377.2M	$304.8M	$200.7M	$153.2M	$154.7M	$137.9M	$106.0M	$89.10M	$72.60M	$55.59M	$20.13M	$7.928M	$5.080M	$4.600M	$4.300M	$4.000M
YoY Change	-10.83%	23.78%	51.87%	30.95%	-0.94%	12.18%	30.1%	18.97%	22.73%	30.6%	176.13%	153.94%	56.06%	10.43%	6.98%	7.5%	2.56%
% of Gross Profit	64.22%	65.04%	60.38%	42.89%	40.75%	39.31%	48.05%	52.22%	64.1%	83.54%	509.3%	1342.13%	991.0%
Research & Development	$91.59M	$74.55M	$90.47M	$75.96M	$69.10M	$89.21M	$49.58M	$42.80M	$29.10M	$19.60M	$17.25M	$23.52M	$30.63M	$35.15M	$29.30M	$30.50M	$19.30M
YoY Change	22.86%	-17.59%	19.1%	9.93%	-22.54%	79.94%	15.83%	47.08%	48.47%	13.66%	-26.67%	-23.21%	-12.87%	19.96%	-3.93%	58.03%	114.44%
% of Gross Profit	17.49%	12.85%	17.92%	16.23%	18.37%	22.67%	17.27%	21.08%	20.94%	22.55%	157.99%	1567.8%	3828.38%
Depreciation & Amortization	$84.86M	$85.54M	$32.60M	$18.14M	$6.659M	$7.063M	$8.132M	$2.400M	$900.0K	$900.0K	$742.0K	$871.0K	$879.0K	$1.188M	$1.100M	$1.100M	$900.0K
YoY Change	-0.8%	162.44%	79.68%	172.43%	-5.72%	-13.15%	238.83%	166.67%	0.0%	21.29%	-14.81%	-0.91%	-26.01%	8.0%	0.0%	22.22%
% of Gross Profit	16.2%	14.75%	6.46%	3.88%	1.77%	1.79%	2.83%	1.18%	0.65%	1.04%	6.8%	58.07%	109.88%
Operating Expenses	$508.8M	$451.8M	$395.2M	$276.6M	$222.3M	$243.9M	$187.5M	$148.8M	$118.3M	$92.10M	$72.84M	$43.65M	$38.56M	$40.23M	$33.90M	$34.70M	$23.30M
YoY Change	12.63%	14.31%	42.87%	24.42%	-8.84%	30.1%	26.0%	25.78%	28.45%	26.45%	66.87%	13.21%	-4.16%	18.67%	-2.31%	48.93%	80.62%
Operating Profit	$14.92M	$46.12M	$86.03M	$173.7M	$148.6M	$144.4M	$99.54M	$54.20M	$20.70M	-$5.200M	-$61.92M	-$42.17M	-$37.75M	-$40.12M
YoY Change	-67.65%	-46.39%	-50.47%	16.91%	2.86%	45.11%	83.65%	161.84%	-498.08%	-91.6%	46.84%	11.7%	-5.91%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Interest Expense	$8.600M	$17.04M	$19.70M	$19.44M	$18.21M	$13.84M	$134.0K	$1.400M	-$400.0K	-$1.800M	$7.849M	$3.575M	$1.866M	$100.0K	$100.0K	-$7.600M	$1.800M
YoY Change	-49.52%	-13.51%	1.34%	6.74%	31.55%	10228.36%	-90.43%	-450.0%	-77.78%	-122.93%	119.55%	91.59%	1766.0%	0.0%	-101.32%	-522.22%	5.88%
% of Operating Profit	57.64%	36.93%	22.89%	11.19%	12.25%	9.58%	0.13%	2.58%	-1.93%
Other Income/Expense, Net	-$562.0K	$14.62M	-$12.85M	-$5.050M	-$1.084M	-$4.268M	$1.077M	-$4.600M	-$3.500M	-$600.0K	-$30.35M	-$4.115M	-$1.718M	$649.0K	$0.00	$0.00	$0.00
YoY Change	-103.84%	-213.73%	154.53%	365.87%	-74.6%	-496.29%	-123.41%	31.43%	483.33%	-98.02%	637.62%	139.52%	-364.71%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Pretax Income	$2.769M	$60.74M	$73.18M	$168.6M	$147.5M	$140.2M	$100.6M	$50.40M	$14.60M	-$10.30M	-$92.27M	-$46.28M	-$39.47M	-$39.47M	$4.100M	-$33.50M	-$17.30M
YoY Change	-95.44%	-16.99%	-56.61%	14.35%	5.22%	39.32%	99.64%	245.21%	-241.75%	-88.84%	99.36%	17.26%	-0.01%	-1062.78%	-112.24%	93.64%	253.06%
Income Tax	$1.453M	$32.00K	$19.75M	$41.70M	$34.43M	$29.18M	$43.33M	-$40.90M	$700.0K	$600.0K	$0.00	$0.00	-$16.25M	-$399.0K	$0.00	$0.00	$0.00
% Of Pretax Income	52.47%	0.05%	26.99%	24.72%	23.35%	20.82%	43.07%	-81.15%	4.79%						0.0%
Net Earnings	$1.316M	$60.71M	$53.42M	$127.0M	$113.1M	$111.0M	$57.28M	$91.20M	$13.90M	-$10.90M	-$92.30M	-$46.28M	$53.82M	-$38.46M	$500.0K	-$33.50M	-$17.30M
YoY Change	-97.83%	13.64%	-57.92%	12.29%	1.86%	93.76%	-37.19%	556.12%	-227.52%	-88.19%	99.42%	-186.01%	-239.91%	-7792.6%	-101.49%	93.64%	253.06%
Net Earnings / Revenue	0.22%	9.1%	9.21%	24.39%	28.79%	27.14%	18.95%	42.42%	9.42%	-11.76%	-767.95%	-3127.3%	6701.74%	-36285.85%	1.32%	-376.4%	-411.9%
Basic Earnings Per Share		$1.13	$1.01	$2.41	$2.16	$2.13	$1.13
Diluted Earnings Per Share	$0.02	$1.04	$0.98	$2.36	$2.10	$2.05	$1.08	$1.764M	$271.5K	-$257.7K	-$2.903M	-$2.661M	$2.251M	-$1.611M	$20.92K	-$1.402M	-$723.8K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Cash & Short-Term Investments	$254.9M	$461.3M	$339.7M	$422.5M	$347.1M	$356.0M	$140.0M	$90.10M	$62.20M	$74.30M	$82.20M	$88.50M	$48.50M	$32.70M	$66.50M	$60.40M
YoY Change	-44.75%	35.81%	-19.6%	21.72%	-2.5%	154.29%	55.38%	44.86%	-16.29%	-9.61%	-7.12%	82.47%	48.32%	-50.83%	10.1%
Cash & Equivalents	$75.05M	$93.12M	$203.4M	$288.6M	$181.4M	$192.2M	$100.3M	$66.40M	$33.50M	$36.40M	$33.00M	$40.30M	$48.50M	$23.70M	$31.40M	$52.90M
Short-Term Investments	$179.8M	$368.2M	$136.2M	$133.9M	$165.7M	$163.8M	$39.70M	$23.70M	$28.70M	$37.90M	$49.20M	$48.20M	$0.00	$9.000M	$35.10M	$7.500M
Other Short-Term Assets	$16.68M	$15.78M	$27.02M	$18.70M	$11.60M	$8.900M	$6.500M	$3.000M	$5.300M	$3.700M	$2.800M	$1.100M	$900.0K	$7.000M	$2.600M	$6.800M
YoY Change	5.68%	-41.6%	44.49%	61.21%	30.34%	36.92%	116.67%	-43.4%	43.24%	32.14%	154.55%	22.22%	-87.14%	169.23%	-61.76%
Inventory	$77.41M	$91.54M	$85.96M	$48.30M	$26.60M	$25.70M	$16.30M	$16.80M	$12.60M	$13.40M	$7.200M	$1.200M	$0.00
Prepaid Expenses
Receivables	$144.2M	$165.5M	$148.9M	$140.9M	$87.30M	$102.9M	$65.60M	$41.50M	$25.90M	$17.30M	$5.100M	$0.00	$0.00	$0.00	$3.400M	$2.300M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$700.0K	$0.00	$200.0K	$300.0K	$0.00
Total Short-Term Assets	$493.1M	$734.2M	$601.6M	$630.4M	$472.6M	$493.5M	$228.5M	$151.4M	$105.9M	$108.7M	$97.20M	$91.50M	$49.40M	$39.80M	$72.90M	$69.50M
YoY Change	-32.83%	22.04%	-4.57%	33.39%	-4.24%	115.97%	50.92%	42.97%	-2.58%	11.83%	6.23%	85.22%	24.12%	-45.4%	4.89%
Property, Plant & Equipment	$42.52M	$44.08M	$52.32M	$58.10M	$38.30M	$4.100M	$5.100M	$4.300M	$3.900M	$2.400M	$2.600M	$1.400M	$1.300M	$1.200M	$1.900M	$2.000M
YoY Change	-3.52%	-15.75%	-9.95%	51.7%	834.15%	-19.61%	18.6%	10.26%	62.5%	-7.69%	85.71%	7.69%	8.33%	-36.84%	-5.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$16.62M	$93.90M	$119.2M	$350.4M	$591.8M	$418.8M	$133.6M	$75.40M	$55.00M	$19.80M	$8.800M	$0.00
YoY Change	-82.3%	-21.21%	-65.99%	-40.79%	41.31%	213.47%	77.19%	37.09%	177.78%	125.0%
Other Assets	$8.511M	$10.90M	$13.87M	$23.00M	$32.70M	$30.10M	$21.20M	$61.90M	$22.80M	$400.0K	$1.400M	$400.0K	$2.100M	$4.800M	$3.800M	$4.100M
YoY Change	-21.93%	-21.38%	-39.71%	-29.66%	8.64%	41.98%	-65.75%	171.49%	5600.0%	-71.43%	250.0%	-80.95%	-56.25%	26.32%	-7.32%
Total Long-Term Assets	$784.6M	$968.4M	$1.088B	$873.7M	$687.7M	$484.3M	$196.0M	$158.2M	$82.70M	$28.10M	$13.80M	$2.500M	$4.300M	$7.200M	$7.000M	$7.600M
YoY Change	-18.98%	-10.96%	24.48%	27.05%	42.0%	147.09%	23.89%	91.29%	194.31%	103.62%	452.0%	-41.86%	-40.28%	2.86%	-7.89%
Total Assets	$1.278B	$1.703B	$1.689B	$1.504B	$1.160B	$977.8M	$424.5M	$309.6M	$188.6M	$136.8M	$111.0M	$94.00M	$53.70M	$47.00M	$79.90M	$77.10M
YoY Change
Accounts Payable	$1.964M	$10.54M	$9.331M	$6.100M	$10.10M	$3.200M	$6.800M	$8.100M	$4.300M	$1.900M	$3.100M	$8.000M	$2.500M	$11.30M	$6.200M	$4.500M
YoY Change	-81.37%	12.99%	52.97%	-39.6%	215.63%	-52.94%	-16.05%	88.37%	126.32%	-38.71%	-61.25%	220.0%	-77.88%	82.26%	37.78%
Accrued Expenses	$231.9M	$237.5M	$241.1M	$189.4M	$144.8M	$143.6M	$95.60M	$69.40M	$51.90M	$26.10M	$15.20M	$2.700M	$9.300M	$1.400M	$3.800M	$3.800M
YoY Change	-2.35%	-1.5%	27.28%	30.8%	0.84%	50.21%	37.75%	33.72%	98.85%	71.71%	462.96%	-70.97%	564.29%	-63.16%	0.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$402.0M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due			$0.00	$3.800M								$11.80M	$6.800M
YoY Change			-100.0%									73.53%
Total Short-Term Liabilities	$290.2M	$688.0M	$315.4M	$245.1M	$160.6M	$161.4M	$123.0M	$80.70M	$56.90M	$28.10M	$26.40M	$23.00M	$18.80M	$15.20M	$10.00M	$8.300M
YoY Change	-57.82%	118.14%	28.67%	52.62%	-0.5%	31.22%	52.42%	41.83%	102.49%	6.44%	14.78%	22.34%	23.68%	52.0%	20.48%
Long-Term Debt	$0.00	$0.00	$379.3M	$382.0M	$345.2M	$329.5M	$0.00	$4.200M	$7.100M	$26.20M	$34.40M	$11.10M	$22.70M	$0.00	$75.00M	$75.00M
YoY Change		-100.0%	-0.72%	10.66%	4.76%		-100.0%	-40.85%	-72.9%	-23.84%	209.91%	-51.1%		-100.0%	0.0%
Other Long-Term Liabilities	$41.00M	$78.54M	$93.32M	$96.90M	$59.10M	$34.00M	$34.00M	$32.90M	$36.60M	$41.70M	$16.70M	$2.300M	$2.800M	$76.10M	$1.000M	$600.0K
YoY Change	-47.8%	-15.84%	-3.7%	63.96%	73.82%	0.0%	3.34%	-10.11%	-12.23%	149.7%	626.09%	-17.86%	-96.32%	7510.0%	66.67%
Total Long-Term Liabilities	$41.00M	$78.54M	$472.6M	$478.9M	$404.3M	$363.5M	$34.00M	$37.10M	$43.70M	$67.90M	$51.10M	$13.40M	$25.50M	$76.10M	$76.00M	$75.60M
YoY Change	-47.8%	-83.38%	-1.32%	18.45%	11.22%	969.12%	-8.36%	-15.1%	-35.64%	32.88%	281.34%	-47.45%	-66.49%	0.13%	0.53%
Total Liabilities	$356.2M	$816.3M	$873.3M	$759.2M	$564.9M	$524.8M	$157.0M	$117.8M	$100.6M	$96.10M	$77.50M	$36.40M	$44.30M	$91.30M	$86.10M	$83.90M
YoY Change	-56.37%	-6.53%	15.03%	34.4%	7.64%	234.27%	33.28%	17.1%	4.68%	24.0%	112.91%	-17.83%	-51.48%	6.04%	2.62%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2012	2011	2010
Basic Shares Outstanding	53.67M shares	53.10M shares	52.62M shares	52.41M shares	51.99M shares	50.76M shares	49.47M	47.49M	42.26M	17.44M shares	1.605M shares	1.588M shares
Diluted Shares Outstanding	61.68M shares	54.36M shares	53.69M shares	53.82M shares	54.10M shares	53.30M shares				17.44M shares	1.605M shares	1.588M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $2.0514 Billion

About SUPERNUS PHARMACEUTICALS, INC.

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 652 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The firm is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals, Inc. Axsome Therapeutics, Inc. CASSAVA SCIENCES INC JOHNSON & JOHNSON Revance Therapeutics, Inc. Tilray Brands, Inc. Ventyx Biosciences, Inc.